Page 175 - Screening for Cervical Cancer: Systematic Evidence Review
P. 175
Screening for Cervical Cancer
HPV Testing as a Triage Tool Among Women with an Abnormal Pap Test for Detection of HSIL*
True Neg Pos Prev False LR LR NPV PPV HGSIL Spec Pos. Neg 0.6 1.6 91.0 21.7 14.5 60.1 155 233 0.1 1.6 94.7 39.8 29.5 40.3 80 54 0.2 2.3 94.0 42.2 24.0 62.2 48 79 0.1 3.3 98.0 37.2 15.4 71.8 59 150 0.2 2.5 98.8 15.1 6.7 64.1 326 582 0.3 2.9 75.2 77.6 54.5 72.4 45 118 0.5 1.7 61.9 67.0 54.5 58.9 67 96 0.5 1.3 89.0 24.4 20.2 34.9 270 145 0.5 1.4 89.2 26.2 20.2 43.6 234 181 0.4 1.7 87.7 38.5 27.4 51.3 598 629 0.3 2.1 96.6 22.1 12.0 59.6 619 913
Sens 65.2 94.6 87.5 92.1 89.2 80.0 69.7 82.9 79.0 81.0 84.6
False Neg 23 3 5 3 7 39 59 18 22 88 32
True Pos. 43 53 35 35 58 156 136 87 83 374 176
Total N 454 190 167 247 973 358 358 520 520 1689 1740 *HPV, human papilloma virus; HSIL, high-grade squamous intraepithelial lesion.
Test Method Consensu s PCR SHARP PCR Consensu s PCR II HC II HC Consensu s PCR I HC Consensu s PCR II HC
Table 11. Author (Year) Adam et al., 1998 71 Bollen et al., 1997 66 Herrington et al., 1995 69 Hillemanns et al., 1999 72 Manos et al., 1999 68 Sigurdsson et al., 1997 67 Sun et al., 1995 73 PCR all Total all HC II
Total
74
